TRIGR Therapeutics Completes $14 Million Seed Round and Provides Phase 1a Clinical Update on its Lead Bispecific Oncology Candidate, TR009
- Written by EQS Asia Business News
DGAP-News: TRIGR Therapeutics, Inc. / Key word(s): Miscellaneous25.03.2019 / 21:32 The issuer is solely responsible for the content of this announcement. IRVINE, CA / ACCESSWIRE / March 25, 2019 / TRIGR Therapeutics, Inc. (''TRIGR''), a newly formed privately held company focused on the clinical development and commercialization of targeted and... |